Kyocera (OTCMKTS:KYOCY) Releases FY 2025 Earnings Guidance

Kyocera (OTCMKTS:KYOCY) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.340-0.340 for the period. The company issued revenue guidance of $13.6 billion-$13.6 billion.

Kyocera Price Performance

OTCMKTS:KYOCY traded down $0.21 during trading hours on Friday, reaching $9.91. The stock had a trading volume of 74,839 shares, compared to its average volume of 125,614. The stock has a market capitalization of $13.96 billion, a PE ratio of 19.57, a PEG ratio of 1.74 and a beta of 0.29. Kyocera has a 52 week low of $9.87 and a 52 week high of $15.63. The company has a 50 day moving average price of $11.66 and a two-hundred day moving average price of $11.76. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.91 and a current ratio of 3.13.

Kyocera (OTCMKTS:KYOCY) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $3.20 billion for the quarter, compared to analysts’ expectations of $3.22 billion. As a group, sell-side analysts anticipate that Kyocera will post 0.51 earnings per share for the current fiscal year.

Kyocera Company Profile

Kyocera Corporation develops, produces, and distributes products based on fine ceramic technologies in Japan, rest of Asia, Europe, the United States, and internationally. It operates through Core Components Business, Electronic Components Business, and Solutions Business segments. The Core Components Business segment offers components, such as fine ceramic components for semiconductor processing equipment, automotive camera modules, and ceramic packages, as well as organic packages and boards to protect electronic components and ICs to industrial machinery, automotive-related, and the information and communication-related markets; optical components, and jewelry and applied ceramic related products; and medical devices comprising prosthetic joints and dental implants.